Trial
NCT04706507
Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Condition
Acute Respiratory Failure
Intervention
IV Ganciclovir
Why stopped
due to increased mortality and futility analyses
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-12